Spinifex closes Series B with $19M

Australia's Spinifex Pharmaceuticals says its added more than $6 million to its second round, bringing the Series B total to $19 million. GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management, and UniQuest all chipped in with cash, which is being earmarked for a mid-stage study of EMA401 for neuropathic pain. Story

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.